---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-25-000058"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:23:49.311551+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veracyte Q1 2025 revenue $114.5M (+18% YoY); net income $7.0M, Decipher revenue up 33%

## Summary
- Total revenue $114.5M (+18% YoY); testing revenue $107.3M (+19%); total test volume 40,655 (+22%).
- Decipher revenue $66.6M (+33%); Afirma revenue $38.3M (+6%); Decipher volume ~22,600 (+37%).
- Net income $7.0M (6.2% of revenue); adjusted EBITDA $24.7M (21.6% of revenue).
- Launched limited access to Decipher for metastatic prostate cancer, expanding addressable population.
- Cash and short-term investments $287.4M; generated $5.4M cash from ops.

## SEC filing metadata
- accession: 0001384101-25-000058
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410125000058/0001384101-25-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410125000058/vcyt-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-25-000058
- JSON: https://secwatch.observer/filing/0001384101-25-000058.json
- Plain text: https://secwatch.observer/filing/0001384101-25-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.